Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)

Press Releases

We are keeping you informed! If you have questions regarding our press releases, feel free to contact us via the website´s contact form. Stay up-to-date with our companies latest news:

Eckert & Ziegler BEBIG: Annual Report 2013 published

Regulated Information

Seneffe - Belgium, March 27, 2014 - Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) announces today that its annual financial report for the year ending December 31, 2013 is now available on the company`s website:

Sales for 2013 were 27.8 million EUR, compared to 31.8 million EUR in 2012, a decrease of 12.4%. Earnings per share has decreased from 0.22 EUR (2012) to 0.20 EUR in 2013.

Shareholders Calendar:
Interim Statement 1Q-2014: Tuesday, May 6, 2014
Annual General Meeting: Thursday, June 12, 2014 (11:30 am)
Half-Year Results 2014: Tuesday, August 5, 2014
Interim Statement 3Q-2014: Thursday, November 6, 2014

The results and trading updates will be published before market opens on the respective dates.

Eckert & Ziegler BEBIG
...Contributing to saving lives!

Eckert & Ziegler BEBIG is a European-based group, active in the medical device sector of the healthcare industry.

Its core business is the treatment of cancer by brachytherapy, a special form of radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and is headquartered in Belgium. It has production facilities in in both Germany and the USA and subsidiaries throughout Europe, as well as in India and in Brazil. Eckert & Ziegler BEBIG has also established a worldwide network of distributors and agents to support its product line.

The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.

Eckert & Ziegler BEBIG employs about 200 people. It has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB).

Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel.: +32 (0) 64 520 808